Augere Medical Strengthens Its Management Team
Recently, Augere Medical has taken strategic steps to bolster its management team following the successful certification of its Class IIb PolypAID™ system. This comes at a significant turning point, as the company aims to solidify its position in the medical technology market.
Leadership Expansion to Drive Commercial Activities
Jon H. Hoem is stepping into the CEO role, bringing a wealth of experience to the position. He is joined by a skilled management team that includes Pia H. Smedsrud as Chief Medical Officer, Tor Jan Berstad as Chief Technology Officer, Daniel Mork Engen overseeing Quality Assurance and Regulatory Affairs, David Borge Larsen in Nordic sales, Arne Nilsen focusing on European sales and marketing, and Ali Nobakht as the Chief Strategy Officer.
Board Enhancements
Even Guttormsen has been appointed as the Chair of the Board, indicating a shift towards a more commercially-focused strategy. The new leadership is seen as a positive change that promises to invigorate the company’s approach to its market strategies.
Comments from the New CEO
Jon H. Hoem expressed his enthusiasm about this transition. He remarked, "After some inspiring months as Executive Chair, I'm delighted to take on the daily management of the company. I appreciate the Board's trust placed in me, and I thank David for his efforts during the transition period. Additionally, I am thrilled to welcome Pia in her new role, and I am excited for the contributions Ali will bring to our team during this pivotal year.”
Focus on Growth and Innovation
The newly structured management team is expected to streamline operations, enabling the company to direct its resources towards the European launch of the PolypAID™ system. This focus will not only help expand into additional markets but will also support ongoing advancements in technology related to polyp detection.
Understanding the PolypAID™ System
Augere Medical's PolypAID™ system utilizes cutting-edge Artificial Intelligence to enhance polyp detection rates, a crucial function during colorectal cancer screenings. The innovative technology is being developed in collaboration with leading colonoscopists and supported by notable investments from Norwegian backers, alongside public funding. As Augere strives to ensure their system exceeds expectations, the tagline "Confidence in outcomes™” reflects their commitment to both medical professionals and patients alike.
Company Contact Information
For more inquiries about Augere Medical, reach out to:
Jon H. Hoem
CEO
Mobile: +41 79 606 2 902
Email: jon@augere.md
Frequently Asked Questions
What recent changes has Augere Medical made to its management team?
Augere Medical has appointed Jon H. Hoem as CEO and made multiple additions to its management team to enhance its focus on commercial activities.
What is the PolypAID™ system?
The PolypAID™ system is a medical technology developed by Augere Medical to improve polyp detection rates during colorectal cancer screenings using Artificial Intelligence.
Who has been appointed as Chair of the Board at Augere Medical?
Even Guttormsen has been appointed as the Chair of the Board, aiming to drive the company's commercial success.
Why is the new management structure important for Augere Medical?
The new structure is designed to concentrate resources on the European launch of the PolypAID™ system and innovate technology for polyp detection.
How can I contact Augere Medical for more information?
You can contact Jon H. Hoem, the CEO of Augere Medical, via mobile at +41 79 606 2 902 or by email at jon@augere.md.
